Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04263727 · ClinicalTrials.gov registry record
A Study of Patients With Chronic Disease
A clinical trial, sponsored by Target PharmaSolutions.
- Terminated
- Registry status
- 579
- Enrollment target
NCT04263727 is a clinical trial that was terminated before completion, run by Target PharmaSolutions. The registered enrollment target is 579 participants.
The verdict
NCT04263727 was terminated before completion, sponsored by Target PharmaSolutions.
- TERMINATED
- Registry status
- 579 participants
- Enrollment target
Study Summary
TARGET-RWE is a 10-year, international, longitudinal, observational study of patients with chronic disease designed to specifically address important clinical questions that remain incompletely answered from registration trials. The protocol will follow a master protocol design in which a shared study infrastructure supports progressive development of the registry across the spectrum of chronic diseases.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 579 participants |
| Start Date | 2020-02-27 |
| Est. Completion | 2024-11-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04263727
The ClinicalTrials.gov registry entry for NCT04263727 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 579 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Target PharmaSolutions, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04263727 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04263727 about?
NCT04263727 is a clinical study titled "A Study of Patients With Chronic Disease". TARGET-RWE is a 10-year, international, longitudinal, observational study of patients with chronic disease designed to specifically address important clinical questions that remain incompletely answered from registration trials. The protocol will follow a master protocol design in which a shared stu...
What is the current status of trial NCT04263727?
This trial is currently terminated. The enrollment target is 579 participants. The study started on 2020-02-27. Estimated completion is 2024-11-21.
Who is sponsoring clinical trial NCT04263727?
This trial is sponsored by Target PharmaSolutions, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.